[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:diabetic-nephropathy":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":166,"states":167},"Diabetic Nephropathy",25,18,[8,16,22,28,35,41,47,53,60,67,73,79,85,91,97,103,109,115,121,128,134,140,147,153,160],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05822609","Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes",[12],"Phase 2","RECRUITING","2026-08-26T02:17:39.857430Z","2026-07-05T05:32:16.816518Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07022418","Formoterol in Diabetes",[12],"2026-08-26T02:17:15.156099Z","2026-05-05T02:43:29.054293Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT05759468","NAD Augmentation in Diabetes Kidney Disease",[12],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:28.295861Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT07024823","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort",[32],"Phase 1","2026-08-26T02:16:00.194860Z","2026-07-05T05:32:16.728308Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT03899883","Uric Acid Lowering Trial in Youth Onset T2D",[12],"2026-08-03T00:53:18.104133Z","2026-07-05T03:45:20.245482Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07271186","Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease",[12],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:29.392472Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06466135","Study of WAL0921 in Patients With Glomerular Kidney Diseases",[12],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:28.312447Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT06217302","Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease",[57],"Phase 3","2026-08-26T02:15:52.238965Z","2026-05-05T02:43:28.643705Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT06291155","Mechanism of SGLT2 Inhibition in the Kidney",[64],"Phase 4","2026-08-26T02:18:17.950264Z","2026-05-05T02:43:29.194796Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05918523","A Long-Term Follow-Up Study of Participants Exposed to REACT",[],"2026-08-26T02:17:40.683658Z","2026-05-13T02:55:06.393572Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT04802395","Real World Evidence Clinical Utility Study of KidneyIntelX",[],"2026-08-26T02:18:16.220328Z","2026-05-13T02:55:06.270133Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07444203","Transformative Research in Diabetic Nephropathy 2.0",[],"2026-08-26T02:15:44.309045Z","2026-05-13T02:55:06.704991Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06752577","Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)",[],"2026-08-26T02:15:51.395565Z","2026-05-13T02:55:06.576817Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05692388","Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus",[],"2026-08-26T02:17:58.890423Z","2026-05-13T02:55:06.370780Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05008276","Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)",[],"2026-08-26T02:16:21.385056Z","2026-05-13T02:55:06.278417Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT04334707","Kidney Precision Medicine Project",[],"2026-08-26T02:17:42.501124Z","2026-05-13T02:55:06.249030Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT02986984","Transformative Research in Diabetic Nephropathy",[],"2026-08-26T02:15:14.574786Z","2026-05-13T02:55:06.104676Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT01802034","Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)",[],"2026-08-26T02:16:49.565137Z","2026-05-13T02:55:06.077698Z",{"nct_id":122,"title":123,"phases":124,"status":125,"updated_at":126,"content_modified":127},"NCT07155694","Role of Finerenone in African American Veterans With Diabetic Kidney Disease",[64],"NOT_YET_RECRUITING","2026-08-26T02:15:25.633039Z","2026-05-05T02:43:29.696271Z",{"nct_id":129,"title":130,"phases":131,"status":125,"updated_at":132,"content_modified":133},"NCT07594145","Precision T1D Platform - New Therapies for Cardio-Renal Complications",[12],"2026-08-26T02:18:04.640417Z","2026-05-29T15:36:40.204179Z",{"nct_id":135,"title":136,"phases":137,"status":125,"updated_at":138,"content_modified":139},"NCT06101901","Revealing Engagement Dynamics Among Diabetic Kidney Disease Patients",[],"2026-08-26T02:18:32.765187Z","2026-05-13T02:55:06.414722Z",{"nct_id":141,"title":142,"phases":143,"status":144,"updated_at":145,"content_modified":146},"NCT06790498","Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product",[],"ENROLLING_BY_INVITATION","2026-08-26T02:18:52.966503Z","2026-06-16T05:54:07.770273Z",{"nct_id":148,"title":149,"phases":150,"status":144,"updated_at":151,"content_modified":152},"NCT05514184","Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease",[],"2026-08-26T02:15:15.642947Z","2026-06-16T05:54:08.035828Z",{"nct_id":154,"title":155,"phases":156,"status":157,"updated_at":158,"content_modified":159},"NCT05507892","Renal Mechanism of SGLT2 Inhibition",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:32:10.191597Z","2026-05-05T02:43:28.495600Z",{"nct_id":161,"title":162,"phases":163,"status":157,"updated_at":164,"content_modified":165},"NCT05319990","Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)",[],"2026-08-03T03:02:32.170340Z","2026-05-13T02:55:06.299924Z",[],[168,172,175,179,182,185,188,192,195,199,202,205,208,211],{"state":169,"count":170,"slug":171},"California",7,"california",{"state":173,"count":170,"slug":174},"Colorado","colorado",{"state":176,"count":177,"slug":178},"Illinois",6,"illinois",{"state":180,"count":177,"slug":181},"Michigan","michigan",{"state":183,"count":177,"slug":184},"New York","new-york",{"state":186,"count":177,"slug":187},"Texas","texas",{"state":189,"count":190,"slug":191},"Florida",4,"florida",{"state":193,"count":190,"slug":194},"Washington","washington",{"state":196,"count":197,"slug":198},"Connecticut",3,"connecticut",{"state":200,"count":197,"slug":201},"Massachusetts","massachusetts",{"state":203,"count":197,"slug":204},"North Carolina","north-carolina",{"state":206,"count":197,"slug":207},"Ohio","ohio",{"state":209,"count":197,"slug":210},"Oregon","oregon",{"state":212,"count":197,"slug":213},"Pennsylvania","pennsylvania"]